Matthew Chung, MD
Interventional Cardiology · Richmond, VANPI 1063738011
Payments from drug & device makers
Across 447 payments — averaging $166.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$47K
- Medtronic$8K
- Abbott$6K
- Edwards Lifesciences$5K
- W. L. Gore & Associates, Inc.$4K
- Boston Scientific$1K
- plus $4K from 32 others
What the payments were for
- Consulting fees$11,58016%
- Speaking & faculty fees$32,09343%
- Travel & lodging$13,66018%
- Food & beverage$17,28323%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 88 | $46,773 |
| Medtronic(2 entities) | 112 | $7,765 |
| Abbott | 67 | $6,081 |
| Edwards Lifesciences | 34 | $5,023 |
| W. L. Gore & Associates, Inc. | 4 | $4,174 |
| Boston Scientific | 21 | $1,091 |
| Abiomed | 8 | $792 |
| Shockwave Medical, Inc | 3 | $282 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $276 |
| Cardiovascular Systems Inc. | 4 | $233 |
| Novartis | 10 | $225 |
| E.r. Squibb & Sons, L.L.C. | 9 | $175 |
| Johnson & Johnson | 9 | $175 |
| AstraZeneca | 3 | $161 |
| Pfizer | 8 | $144 |
| Boehringer Ingelheim | 7 | $144 |
| Amgen | 6 | $136 |
| Integra Lifesciences Corporation | 1 | $128 |
| Angiodynamics, Inc. | 3 | $101 |
| Astellas Pharma US Inc | 5 | $92 |
| Novo Nordisk | 4 | $90 |
| Penumbra, Inc. | 3 | $89 |
| Scpharmaceuticals Inc. | 3 | $77 |
| Alnylam Pharmaceuticals Inc. | 4 | $71 |
| Bayer | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 1 | $36 |
| Amarin Pharma, Inc. | 2 | $35 |
| Smith+Nephew | 1 | $30 |
| Cleerly, Inc. | 1 | $28 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Sanofi | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Atricure, Inc. | 1 | $20 |
| Cvrx, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Lemaitre Vascular, Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (R11) US EQ Undivided$15,175
- (9520) IGT Devices Undivided$11,012
- US Und$8,291
- (8328) Image Guided Therapy Devices _ Therapy$4,410
- GORE CARDIOFORM Septal Occluder$4,174
- (7881) Ultrasound Und$4,104
- COREVALVE EVOLUT R$2,895
- SAPIEN 3 Ultra RESILIA$2,622
- Mitra Clip system$1,775
- CoreValve Evolut$1,723
- TRICLIP$1,205
- (6361) Core Mobile$1,101
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$702
- Edwards SAPIEN 3 Transcatheter Heart Valve$667
- PROCLAIM$635
- (6554) Peripheral Vascular Undivided$612
- MitraClip System$426
- INTEGRA$385
- Impella$353
- 3F$260
How this compares
$74,636 in reported general payments places this provider in the 85th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 418 | $400,431 |
| EntrestoSacubitril/Valsartan | 135 | $133,093 |
| XareltoRivaroxaban | 82 | $93,681 |
| Repatha SureclickEvolocumab | 63 | $66,161 |
| FarxigaDapagliflozin Propanediol | 60 | $48,419 |
| JardianceEmpagliflozin | 11 | $11,281 |
| Metoprolol Succinate | 458 | $5,738 |
| Ranolazine ErRanolazine | 26 | $4,443 |
| Carvedilol | 421 | $3,742 |
| Losartan Potassium | 474 | $3,666 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 205 | $3,647 |
| Midodrine Hcl | 33 | $3,611 |
| Bumetanide | 110 | $3,573 |
| ClopidogrelClopidogrel Bisulfate | 251 | $3,056 |
| Rosuvastatin Calcium | 196 | $2,602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $144 | $400,431418 claims |
| NovartisEntresto | $225 | $133,093135 claims |
| Johnson & JohnsonXarelto | $175 | $93,68182 claims |
| AstraZenecaFarxiga | $161 | $48,41960 claims |
| Boehringer IngelheimJardiance | $144 | $11,28111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Richmond
- Gansevoort DunningtonRichmond$440K
- Rakesh JainRichmond$331K
- Nayef AbouzakiRichmond$250K
- Ion JovinRichmond$116K
- Michael ArcareseRichmond$88K
- Zachary GertzRichmond$36K
- Ashwani KumarRichmond$35K
- Brinder KandaRichmond$34K
- James GarnettRichmond$19K
- Barbara LawsonRichmond$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.